WHO guidelines for the management of postpartum haemorrhage ...
WHO guidelines for the management of postpartum haemorrhage ...
WHO guidelines for the management of postpartum haemorrhage ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>WHO</strong> <strong>guidelines</strong> <strong>for</strong> <strong>the</strong> <strong>management</strong> <strong>of</strong> <strong>postpartum</strong> <strong>haemorrhage</strong> and retained placenta<br />
D. Choice <strong>of</strong> fluid <strong>for</strong> replacement or resuscitation<br />
Table D1. Colloids vs crystalloids <strong>for</strong> fluid replacement in critically ill patients (193)<br />
Quality assessment<br />
No. <strong>of</strong><br />
studies<br />
Design Limitations Inconsistency Indirectness Imprecision<br />
O<strong>the</strong>r<br />
considerations<br />
Death (albumin or plasma protein fraction vs crystalloids)<br />
23 Randomized<br />
trial<br />
No serious<br />
limitations<br />
No serious<br />
inconsistency<br />
No serious<br />
indirectness<br />
No serious<br />
imprecision<br />
None<br />
Death (hydroxyethyl starch vs crystalloids)<br />
16 Randomized<br />
trial<br />
No serious<br />
limitations<br />
No serious<br />
inconsistency<br />
No serious<br />
indirectness<br />
No serious<br />
imprecision<br />
None<br />
Death (modified gelatin vs crystalloids)<br />
11 Randomized<br />
trial<br />
No serious<br />
limitations<br />
No serious<br />
inconsistency<br />
No serious<br />
indirectness<br />
No serious<br />
imprecision<br />
None<br />
Death (dextran vs crystalloids)<br />
9 Randomized<br />
trial<br />
No serious<br />
limitations<br />
No serious<br />
inconsistency<br />
No serious<br />
indirectness<br />
No serious<br />
imprecision<br />
None<br />
Summary <strong>of</strong> findings<br />
No. <strong>of</strong> patients Effect<br />
Colloids Crystalloids<br />
Relative<br />
(95% CI)<br />
Absolute<br />
Quality<br />
782/3870<br />
(20.2%)<br />
778/3884<br />
(20%)<br />
RR 1.01<br />
(0.92–1.1)<br />
2 more per<br />
1000 (from<br />
16 fewer to<br />
20 more)<br />
High<br />
24/375<br />
(6.4%)<br />
18/262 (6.9%)<br />
RR 1.05<br />
(0.63–<br />
1.75)<br />
3 more per<br />
1000 High<br />
13/224<br />
(5.8%)<br />
15/282 (5.3%)<br />
RR 0.91<br />
(0.49–<br />
1.72)<br />
4 fewer per<br />
1000 High<br />
96/412<br />
(23.3%)<br />
57/422<br />
(13.5%)<br />
RR 1.24<br />
(0.94–<br />
1.65)<br />
32 more<br />
per 1000 High<br />
Importance<br />
Critical<br />
Critical<br />
Critical<br />
Critical<br />
38
Change language